Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

References

• Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26:91 - 102; http://dx.doi.org/10.1053/ctrv.1999.0151; PMID: 10772967
   PubMed Web of Science ®Google Scholar
• Bast RC Jr., Ravdin P, Hayes DF, Bates S, Fritsche H Jr., Jessup JM, et al. American Society of Clinical Oncology Tumor Makers Expert Panel: 2000 update of recommendations for the use of tumor makers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865 - 78; PMID: 11251019
   PubMed Web of Science ®Google Scholar
• Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu noz M, et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998; 51:109 - 19; http://dx.doi.org/10.1023/A:1005734429304; PMID: 9879773
   PubMed Web of Science ®Google Scholar
• Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658 - 67; http://dx.doi.org/10.1001/jama.295.14.1658; PMID: 16609087
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH, et al, National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103 - 11; http://dx.doi.org/10.1056/NEJMoa054504; PMID: 16707747
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27:2809 - 15; http://dx.doi.org/10.1200/JCO.2008.18.2808; PMID: 19380452
   PubMed Web of Science ®Google Scholar
• Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644 - 6; http://dx.doi.org/10.1126/science.3012781; PMID: 3012781
   PubMed Web of Science ®Google Scholar
• Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198:165 - 84; PMID: 7819273
   PubMed Web of Science ®Google Scholar
• Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998; 20:41 - 8; http://dx.doi.org/10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; PMID: 9504046
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37:Suppl 4 3 - 8; http://dx.doi.org/10.1016/S0959-8049(01)00230-1; PMID: 11342194
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177 - 82; http://dx.doi.org/10.1126/science.3798106; PMID: 3798106
   PubMed Web of Science ®Google Scholar
• Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16:462 - 9; PMID: 9469329
   PubMed Web of Science ®Google Scholar
• Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006; 24:5658 - 63; http://dx.doi.org/10.1200/JCO.2006.07.0250; PMID: 17102066
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719 - 26; http://dx.doi.org/10.1200/JCO.20.3.719; PMID: 11821453
   PubMed Web of Science ®Google Scholar
• Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999; 17:434; PMID: 10458264
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783 - 92; http://dx.doi.org/10.1056/NEJM200103153441101; PMID: 11248153
   PubMed Web of Science ®Google Scholar
• Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18:3651 - 64; PMID: 11054438
   PubMed Web of Science ®Google Scholar
• Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54:2771 - 7; PMID: 7909495
   PubMed Web of Science ®Google Scholar
• Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991; 266:1716 - 20; PMID: 1671042
   PubMed Web of Science ®Google Scholar
• Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992; 10:1436 - 43; PMID: 1355522
   PubMed Web of Science ®Google Scholar
• Lüftner D, Cheli C, Mickelson K, Sampson E, Possinger K. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers 2004; 19:175 - 82; PMID: 15503818
   PubMed Web of Science ®Google Scholar
• Kuroda N, Kontani K, Kajikawa T, Taminato T. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method. Rinsho Byori 2010; 58:541 - 52; PMID: 20662264
   PubMedGoogle Scholar
• Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003; 49:1579 - 98; http://dx.doi.org/10.1373/49.10.1579; PMID: 14500583
   PubMed Web of Science ®Google Scholar
• Carney WP. The Emerging Role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Lab Med 2003; 34:58 - 64; http://dx.doi.org/10.1309/TY6M-DWB0-G2BU-6D5F
   Google Scholar
• Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al, National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54:e11 - 79; http://dx.doi.org/10.1373/clinchem.2008.105601; PMID: 19042984
   PubMed Web of Science ®Google Scholar
• Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, et al, Cancer and Leukemia Group B. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001; 7:2703 - 11; PMID: 11555582
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20:1467 - 72; http://dx.doi.org/10.1200/JCO.20.6.1467; PMID: 11896093
   PubMed Web of Science ®Google Scholar
• Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 2007; 110:2178 - 85; http://dx.doi.org/10.1002/cncr.23043; PMID: 17926331
   PubMed Web of Science ®Google Scholar
• Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6:2356 - 62; PMID: 10873087
   PubMed Web of Science ®Google Scholar
• Köstler WJ, Schwab B, Singer CF, Neumann R, Rücklinger E, Brodowicz T, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004; 10:1618 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-0385-3; PMID: 15014012
   PubMed Web of Science ®Google Scholar
• Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, et al, Serum HER-2/neu Study Group. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008; 113:1294 - 301; http://dx.doi.org/10.1002/cncr.23689; PMID: 18661530
   PubMed Web of Science ®Google Scholar
• Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997; 18:188 - 96; http://dx.doi.org/10.1159/000218029; PMID: 9143415
   PubMed Web of Science ®Google Scholar
• Kashiwaba M, Hayakawa Y, Takiyama I, Inaba R, Itoh N, Saito K. Nihon Gekagakkaizasshi 2005; 106:587
   Google Scholar
• Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al, HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29 - 36; http://dx.doi.org/10.1016/S0140-6736(07)60028-2; PMID: 17208639
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13:228 - 33; http://dx.doi.org/10.1158/1078-0432.CCR-06-1345; PMID: 17200359
   PubMed Web of Science ®Google Scholar
• Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29:149 - 56; http://dx.doi.org/10.1200/JCO.2010.28.6450; PMID: 21115860
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783 - 92; http://dx.doi.org/10.1056/NEJM200103153441101; PMID: 11248153
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99:628 - 38; http://dx.doi.org/10.1093/jnci/djk134; PMID: 17440164
   PubMed Web of Science ®Google Scholar
• Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744 - 9; PMID: 11406546
   PubMed Web of Science ®Google Scholar
• Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009; 27:1694 - 705; http://dx.doi.org/10.1200/JCO.2008.17.3989; PMID: 19255333
   PubMed Web of Science ®Google Scholar